AV Laboratories Joins Regenivus (Mitrone Healthcare Ltd.) at Dublin’s Aesthetic & Regenerative Medicine Conference

AV Laboratories Joins Regenivus (Mitrone Healthcare Ltd.) at Dublin’s Aesthetic & Regenerative Medicine Conference




AV Laboratories Joins Regenivus (Mitrone Healthcare Ltd.) at Dublin’s Aesthetic & Regenerative Medicine Conference

DUBLIN–(BUSINESS WIRE)–AV Laboratories, a clinical skin longevity brand bridging advanced formulation science and skincare innovation, is pleased to announce its participation in The Aesthetic & Regenerative Medicine Conference, taking place on 18–19 October 2026 at Croke Park, Dublin.




The brand will join Regenivus, the aesthetics sub-brand of Mitrone Healthcare Ltd., an established Irish healthcare distributor with expertise in specialist medical technologies and regenerative medicine. The collaboration represents an opportunity to introduce AV Laboratories’ science-led skincare portfolio to Ireland’s professional aesthetic medicine community.

The two-day conference brings together clinicians, researchers and industry innovators to explore advancements in aesthetic and regenerative medicine, with an emphasis on scientific evidence, clinical excellence and multidisciplinary collaboration.

AV Laboratories’ participation reflects its growing international presence and commitment to connecting advanced skincare science with professional clinical practice.

The brand will be represented by Sylwia Pawlaczyk, Chief Operating Officer and Master Formulator at AV Laboratories, who will attend the conference to engage directly with aesthetic medicine practitioners, clinic owners and healthcare professionals.

With a background in chemistry, formulation development and product safety, Pawlaczyk oversees the scientific development, formulation strategy and regulatory compliance of the AV Laboratories portfolio. Her presence will provide delegates with an opportunity to discuss the scientific rationale behind the brand’s formulations, its proprietary AVL SOM3® technology, and the role of advanced topical skincare in aesthetic care.

At the Regenivus exhibition stand, visitors will have the opportunity to discover the AV Laboratories product portfolio and learn more about its clinical partnership programme for aesthetic medicine clinics, including the integration of its skincare products into professional treatment protocols, complementary skincare recommendations and long-term patient skincare routines.

Discussions will also cover formulation science, clinical evaluation, the brand’s scientific development programme and opportunities for collaboration with clinics interested in introducing AV Laboratories products into their professional offering.

Through its collaboration with Regenivus and AV Laboratories aims to strengthen its position within Ireland’s professional aesthetics sector and foster meaningful partnerships at the intersection of skincare science, regenerative medicine and clinical innovation.

Healthcare professionals, aesthetic practitioners and clinic representatives attending the conference are invited to visit the Regenivus booth and meet AV Laboratories COO and Master Formulator Sylwia Pawlaczyk, and explore opportunities for clinical collaboration.

About AV Laboratories

AV Laboratories is a clinical skin longevity brand developing advanced topical skincare formulations inspired by decades of research in cellular culture environments. At the core of its portfolio is AVL SOM3®, a proprietary technology originating from the science of cell culture media.

Combining formulation expertise, scientific research and a commitment to product safety, AV Laboratories develops sophisticated skincare products designed for daily use and integration into professional aesthetic environments.

About Regenivus

Regenivus is an established Irish healthcare distributor specialising in medical technologies and solutions for clinical professionals. Building on Mitrone Healthcare’s experience in specialist healthcare markets, Regenivus focuses on bringing innovative products and science-led solutions to the professional aesthetic medicine sector.

Event Details

The Aesthetic & Regenerative Medicine Conference 2026 18–19 October 2026 Croke Park, Dublin, Ireland

Exhibitor: Regenivus featuring AV Laboratories

Contacts

Marlee Martinez, AVL PR Representative – marlee@valleymade.co

Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase

Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase




Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase

– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types –


– New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges impacting radiopharmaceutical development and patient access –

LOS ANGELES–(BUSINESS WIRE)–The Prostate Cancer Foundation (PCF) today announced the expansion of its Radiopharmaceutical Think Tank, adding new members and establishing its 2026-2027 agenda, which is focused on accelerating development and patient access of novel radiopharmaceutical drugs for cancer treatment. PCF is announcing the second year Think Tank program in conjunction with the European Association of Nuclear Medicine (EANM) Annual Congress, taking place October 17-21 in Vienna, Austria.

Radiopharmaceuticals have moved beyond their traditional role in specialized diagnostics to become an increasingly important therapeutic approach in cancer care. In prostate cancer, PSMA-targeted radioligand therapy has helped establish the clinical and commercial potential of this treatment approach, while continued development across prostate cancer and other tumor types is expanding the field. As radiopharmaceutical therapies move into earlier stages of disease and become available to larger patient populations, stakeholders from manufacturers and regulators to treatment centers and payers must work together to ensure patients can access these innovative medicines.

“The science around radiopharmaceuticals is moving quickly, and the systems needed to develop and deliver these therapies have to keep pace to optimize their benefits for patients across a broad range of cancers,” said Oliver Sartor, M.D., Director of the Translational Oncology Research Program at Tulane University School of Medicine and Chair of the Radiopharmaceutical Think Tank. “The Think Tank brings together medical professionals, government experts, and researchers who are on the leading edge of radiopharmaceutical research and clinical practice to solve challenges that will elevate one of oncology’s fastest-growing therapeutic fields.”

PCF established the Radiopharmaceutical Think Tank in October 2025 to bring together senior leaders from industry, medicine and other disciplines involved in radiopharmaceutical development and delivery. In its second year, the Think Tank will focus on identifying and prioritizing barriers to radiopharmaceutical development and access, bringing those issues to broader oncology, regulatory and payer communities, working toward potential solutions, and applying lessons from prostate cancer to radiopharmaceutical development across a variety of tumor types.

“By bringing together the primary drivers in a unique problem-solving forum, the Think Tank can direct unparalleled knowledge to solve the challenges that will take this innovative field to the next level,” said Phillip J. Koo, M.D., Executive Vice President and Chief Medical Officer of the Prostate Cancer Foundation. “Radiopharmaceuticals are creating important new opportunities in prostate cancer treatment, but realizing their full potential for patients with other cancers and diseases requires expertise and coordination from many different areas. PCF is ideally positioned to drive further progress in radiopharmaceuticals, sitting at the center of the research network that helped validate the potential of radioligand therapy.”

New Think Tank members for the 2026-2027 term include Orano Med, Telix Pharmaceuticals and Siemens Healthineers. They join existing members Actithera, Advancell, Artbio, AstraZeneca, Bayer, Bicycle Therapeutics, Clarity Pharmaceuticals, Curium and Novartis. Beginning with its kickoff meeting at the EANM Annual Congress this month, the Think Tank will convene four times during its new term.

About the Prostate Cancer Foundation

The Prostate Cancer Foundation® (PCF®) is the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has raised more than $1.2 billion to fund cutting-edge research through more than 2,615 research projects at 312 leading cancer centers, with a global footprint spanning 29 countries. Since PCF’s inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to the mission of ending death and suffering from this disease. Learn more at PCF.org.

Contacts

MEDIA CONTACT:
Mike Beyer

Sam Brown Inc.

mikebeyer@sambrown.com

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes




FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

  • One drop works to significantly reduce redness, with results lasting up to 12 hours1
  • Lasts up to 50% longer than Lumify1-2,*
  • Expands Alcon’s portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months

GENEVA–(BUSINESS WIRE)–Regulatory News:




Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration (FDA) has approved BRYTLY® Redness Reliever Eye Drops. With one drop, BRYTLY works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking eyes.1 Additionally, BRYTLY lasts up to 50% longer than Lumify.1-2,* The approval brings a differentiated new option to the over the counter (OTC) redness-relief category and expands Alcon’s portfolio of trusted consumer eye care products.

Beauty and wellness routines are increasingly converging, with consumers looking for products that combine visible results, clinical validation and everyday convenience. Research has also found that visible eye redness can influence perceptions of healthiness and attractiveness, creating new relevance for the eyes as part of an overall appearance and wellness routine.3 BRYTLY brings a clinically proven option to this evolving space, by reducing redness and helping eyes look whiter and brighter with results that can last throughout the day, up to 12 hours.

“Consumers invest in products that help them look and feel their best, and the appearance of their eyes can be an important part of that,” said Jonathan Balch, General Manager, Ocular Health & Pharmaceuticals, Alcon. “This FDA approval marks an exciting milestone for Alcon. With BRYTLY, we’re bringing Alcon’s trusted eye care expertise to consumers who want to reduce eye redness and want their eyes to look whiter and brighter. BRYTLY is designed to deliver simple, long-lasting redness reduction that can help consumers feel confident in how their eyes look throughout the day.”

BRYTLY contains no bleaches or dyes and is clinically proven to be safe and effective when used as directed.1 Studies also demonstrated a low risk of redness rebound and tachyphylaxis when used as directed.4-5

“When patients ask about eye whiteners, they want a product they can trust to work effectively and fit into their day,” said Selina McGee**, founder and chief optometrist of Bespoke Vision in Edmond, Oklahoma. “BRYTLY gives Eye Care Professionals a clinically proven option to recommend, with demonstrated safety and efficacy and long-lasting redness reduction from a single drop.”

BRYTLY is expected to be available at major retailers nationwide and online in the coming months, and in additional markets in the future.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

*Based on label claim, BRYTLY up to 12 hours / Lumify up to 8 hours.

**Paid Alcon consultant.

References

  1. Alcon- BRYTLY Label, 2026.
  2. BAUSCH + LOMB Lumify Label. DailyMed. Published 2025. Accessed February 19, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=022de945-0b26-40ae-8e88-d3fe2464d106.
  3. Provine RR, Cabrera MO, Nave-Blodgett J. Red, yellow, and super-white sclera: uniquely human cues for healthiness, attractiveness, and age. Human Nature. 2013;24:126–136. doi:10.1007/s12110-013-9168-x.
  4. Alcon data on file, 2025; REF-27135.
  5. Alcon data on file, 2025; REF-27136.

Connect with us on

Facebook
LinkedIn

Contacts

Investor Relations
Dan Cravens, Richard Bourne

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Media Relations
Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

globalmedia.relations@alcon.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)




Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Company’s newly-appointed Senior Vice President, Chief Information Officer, and seventeen other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).


The company granted Mr. Aschettino stock options to purchase 70,000 shares of common stock. The stock options that were granted have an exercise price of $24.61 per share, which is equal to the closing price of Stoke’s common stock on October 15, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

In addition, the company granted stock options to purchase an aggregate of 175,920 shares of common stock to seventeen new employees. The stock options that were granted have an exercise price of $24.61 per share, which is equal to the closing price of Stoke’s common stock on October 15, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

Contacts

Stoke Media & Investor Contacts:
Susan Willson

Vice President, Corporate Communications

swillson@stoketherapeutics.com

415-509-8202

Investor Relations

IR@stoketherapeutics.com
508-642-6485

FamiCord AG: intends capital increase of up to 20 percent against cash contri-butions with subscription rights

FamiCord AG / Key word(s): Capital measures / Capital increase

FamiCord AG: intends capital increase of up to 20 percent against cash contri-butions with subscription rights

16-Oct-2026 / 17:42 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Leipzig, 16 October 2026 – FamiCord AG (ISIN: DE000A0BL849) intends to carry out a capital increase by partially utilizing the Authorized Capital 2024/1 through the issuance of new shares representing up to 20 percent of the Company’s existing share capital. The new shares shall be offered for subscription to the Company’s shareholders. The Company targets gross proceeds from the capital increase of up to EUR 9 million. These proceeds shall be used primarily to stabilize and optimize the core business of cell and tissue banking as well as CDMO activities, to streamline the Group’s structure – including related reorganization and efficiency measures – and to evaluate and selectively pursue growth opportunities in adjacent business areas. The subscription offer is intended to be launched in November 2026. Further details of the capital increase will be announced following the final resolutions of the Management Board and Supervisory Board.

Notifying Person: Jakub Baran (CEO)

DISCLAIMER
This announcement may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction in which such distribution or publication would be unlawful. The distribution of this publication may be restricted by law in certain jurisdictions and anyone in possession of this document or information referred to herein should inform themselves about and observe any such restrictions. Failure to comply with such restrictions may constitute a violation of the capital market laws of such countries.

This announcement does not constitute an offer of, or an invitation to subscribe for or purchase, securities of FamiCord AG in the United States of America, Germany or any other jurisdiction. No public offering has been or will be made and no prospectus has been or will be published in connection with the transaction.

Neither this publication nor its contents may form the basis of an offer in any jurisdiction. The securities referred to above may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “Securities Act”). The securities of FamiCord AG have not been and will not be registered under the Securities Act.

This announcement does not constitute a recommendation regarding the placement of the securities described in this announcement. Investors should consult a professional adviser as to the suitability of the offer for the person concerned.

In the United Kingdom, this publication is directed only at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, partnerships, etc.) (all such persons together being referred to as “Relevant Persons”). This publication must not be acted on or relied on by persons other than Relevant Persons. Any investment or investment opportunity referred to in this publication is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The offer referred to herein, which is being made in Member States of the European Economic Area (each a “Relevant Member State”), is directed only at “qualified investors” as defined in Article 2(e) of the Prospectus Regulation (“Qualified Investors”). For these purposes, the term “Prospectus Regulation” means Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC and includes the related delegated regulations.

No action has been taken that would permit an offering of the securities, their acquisition or the distribution of this publication in countries where this is not permitted. Any person into whose possession this publication comes is required to inform themselves about and to observe any such restrictions.

OTHER
This publication constitutes neither an offer to sell nor a solicitation to buy securities. This announcement may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction in which such publication would be unlawful. This announcement does not constitute a recommendation to buy or sell the securities described in this announcement.
 

End of Inside Information


16-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: FamiCord AG
Perlickstr. 5
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@famicord.com
Internet: www.famicord.com
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900OEWA4GSZEZ4P40
EQS News ID: 2417458

 
End of Announcement EQS News Service

2417458  16-Oct-2026 CET/CEST

PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.

PolyPeptide Group / Key word(s): Tender Offer

PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.

16-Oct-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Media Release – ad hoc announcement pursuant to Art. 53 LR

Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 16 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive interim result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The main offer period of the Offer ended on 12 October 2026, at 4:00 p.m. Swiss time. According to the definitive interim result as published by Samsung Peptide,

  • the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 29,123,892 PolyPeptide shares in aggregate, corresponding to 87.92% of the issued share capital and voting rights of PolyPeptide (participation rate); and
  • 29,014,418 PolyPeptide shares were tendered into the Offer until the end of the main offer period of the Offer, corresponding to 87.59% of the issued share capital and voting rights of PolyPeptide and 87.88% of all PolyPeptide shares to which the Offer relates (success rate).

The definitive interim result that has been published today by Samsung Peptide is available at https://samsungbiologics.com/offer. The provisional and the definitive end result of the Offer will be published after the end of the additional acceptance period (see below).

According to the definitive interim result as published by Samsung Peptide,

  • the Offer condition pursuant to section B.7.1(a) (Minimum Acceptance Rate) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the “Offer Prospectus”) has been satisfied; and
  • the Offer condition pursuant to section B.7.1(d) (No Material Adverse Effect) of the Offer Prospectus has been satisfied.

In its definitive interim result, Samsung Peptide has declared the Offer successful (zustande gekommen), subject to the satisfaction of certain remaining Offer conditions, including among others the receipt of regulatory approvals in certain jurisdictions as well as the removal of the transfer restrictions and voting limitations from PolyPeptide’s articles of association and the election of the persons nominated by Samsung Biologics to the board of directors of PolyPeptide by resolution of an extraordinary general meeting of PolyPeptide. PolyPeptide has invited for an extraordinary general meeting to be held on 26 October 2026 to resolve on these matters.

According to the definitive interim result as published by Samsung Peptide, the additional acceptance period of ten (10) trading days for the subsequent acceptance of the Offer will commence on 19 October 2026 and end on 30 October 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (Additional Acceptance Period) of the Offer Prospectus.

According to the definitive interim result as published by Samsung Peptide, based on the current understanding of the regulatory approval procedures in various countries as set out in the Offer Prospectus (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances)), it is expected that, subject to the satisfaction of all Offer conditions, the settlement of the Offer indicated in the Offer Prospectus to take place on 13 November 2026 will be postponed in accordance with section B.7.3 of the Offer Prospectus, and that the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the definitive interim result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

 

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com 
T: +41 43 502 0580

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com. 

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the definitive interim result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

 

Additional features:

File: 20261016_PolyPeptide_Media_Release_Tender_Offer


End of Inside Information


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2416952

 
End of Announcement EQS News Service

2416952  16-Oct-2026 CET/CEST

Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract

Fresenius SE & Co. KGaA

/ Key word(s): Personnel

Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract (news with additional features)

15.10.2026 / 18:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • Marc-Alexander Mahl appointed to the Fresenius Management Board; Mahl succeeds Pierluigi Antonelli and will be responsible for the Fresenius Kabi businesses
  • Fresenius CFO Sara Hennicken’s contract extended for another five years
  • Sébastien Guery assumes overall responsibility for the Nutrition business at Fresenius Kabi
  • Leadership team set for the next phase of #FutureFresenius

The Supervisory Board of Fresenius has unanimously appointed Dr. Marc-Alexander Mahl (58) to the Fresenius Management Board, effective November 1, 2026. He will be responsible for the Fresenius Kabi businesses. Mahl succeeds Pierluigi Antonelli, who is leaving the company for personal reasons. At the same time, the Supervisory Board has extended the contract of Chief Financial Officer (CFO) Sara Hennicken (46) for another five years. Her contract will therefore run until 2032.

“On behalf of the Supervisory Board, I would like to thank Pierluigi Antonelli for our successful collaboration built on mutual trust. Thanks to the consistent implementation of #FutureFresenius at Fresenius Kabi, all businesses are now excellently positioned in their respective growth markets and make a significant contribution to the company’s success. We wish Mr. Antonelli all the very best in his future endeavors,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. He added: “At the same time, I am delighted that in Marc-Alexander Mahl we have been able to bring an accomplished physician and experienced executive with more than 20 years of leadership experience at Fresenius to the Group Management Board. He is already responsible for two strategically important businesses, Pharma and Nutrition, and has played a key role in shaping their strategic direction as part of #FutureFresenius. The focus now is on consistently expanding the Biopharma, MedTech and Nutrition growth vectors. We very much look forward to working with him in his expanded role and are confident that he will continue the growth trajectory of all Fresenius Kabi businesses.”

Marc-Alexander Mahl will continue to lead the Pharma Business Unit. Given its growing strategic importance, the Nutrition business will in future be managed as a standalone Business Unit under the leadership of Sébastien Guery. Guery has been responsible for the Nutrition business since April 2024 and previously held several management positions at other international companies, including Sandoz, DuPont Nutrition & Biosciences and McKinsey. In his expanded role, Guery will report directly to Marc-Alexander Mahl, who is responsible for the Fresenius Kabi businesses on the Fresenius Management Board.

At the same time, the Supervisory Board has extended the contract of CFO Sara Hennicken for another five years. Her contract will now run until 2032. “Sara Hennicken has played a pivotal role in shaping the successful execution of #FutureFresenius from the very beginning. Thus, we very much look forward to continuing our successful collaboration with her,” said Kirsch.

“I would like to congratulate Sara Hennicken and Marc-Alexander Mahl and very much look forward to continuing our work together on the Management Board. On behalf of the Management Board, I would also like to thank Pierluigi Antonelli for the excellent collaboration over the past years and wish him all the very best for the future. Looking ahead, the medical nutrition business will play an even more important role for the company as a whole. I am therefore very pleased that Sébastien Guery will now assume overall responsibility for the Nutrition business,” added Michael Sen, Chief Executive Officer of Fresenius.

Leadership team set for the next phase of #FutureFresenius
With these decisions and the further strengthening of its operating businesses, Fresenius is putting its leadership team in place for the next phase of #FutureFresenius and underscoring its ambition to create sustainable value through profitable, innovation-driven growth.

Dr. Marc-Alexander Mahl has headed Fresenius’ Pharma and Nutrition businesses since May 2023. In addition, he oversees sustainability activities in these businesses. Mahl has been with Fresenius since July 2001, with a brief interruption, and has since held various management positions with regional and global responsibilities. Since 2011, he has been responsible for the global Pharma business. In parallel, Mahl served as President of Medicines for Europe and as a member of the Executive Committee of the German industry association for specialized nutrition. Mahl studied medicine, is a specialist in transfusion medicine and holds an MBA from INSEAD.

Sara Hennicken has been Chief Financial Officer of Fresenius since September 2022. In this role, she is responsible for Finance, IT and Cybersecurity. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to that, she spent 14 years in investment banking, most recently serving as Managing Director at Deutsche Bank. From 2005 to 2010, Hennicken worked at Citigroup in Frankfurt and London. She studied economics in Germany and the United States.

# # #

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu 
Chairman of the Supervisory Board: Wolfgang Kirsch

Press Contact:
Edith Müller-Callsen
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 160 9968 4046
edith.mueller-callsen@fresenius.com


Additional features:

File: 20261015_FSE_PressRelease_Changes_Mgmt_Board
File: Dr_Marc_Mahl_Fresenius
File: Sara_Hennicken_Fresenius


15.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-97033
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE000FRE5EN2
WKN: FRE5EN
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Hamburg, Hanover, Stuttgart, Tradegate BSX; Luxembourg Stock Exchange
LEI Code: XDFJ0CYCOO1FXRFTQS51
EQS News ID: 2416814

 
End of News EQS News Service

2416814  15.10.2026 CET/CEST

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

invIOs GmbH

/ Key word(s): Scientific publication

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

15.10.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

  • Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors
  • Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites
  • APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade ≥3 treatment-related adverse events
  • Disease stabilization was observed in 5 of 10 RECIST-evaluable patients

Vienna, Austria, 15 October 2026: invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, “Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors”, reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors.

A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade ≥3 treatment-related adverse events. The highest dose of 4.5 × 10⁷ PBMCs/kg was selected as the recommended Phase 2 dose.

Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit.

APN401 is an autologous cell therapy utilizing patients’ own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells.

Romana Gugenberger, PhD, Managing Director of invIOs, commented: “We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors.”

APN401 is produced using invIOs’ proprietary EPiC® point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration.

About invIOs

invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs’ proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient’s fresh immune cells, enabling rapid treatment in an out-patient setting.

The platform’s lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types.

INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications.

For further information, please visit www.invios.com and connect with us on LinkedIn.

Contacts

invIOs
Romana Gugenberger, PhD
Managing Director
T +43 1 8656577 0
Email: investors@invios.com
 
MC Services AG
Dr. Cora Kaiser, Dr. Regina Lutz
T +49 89 210 228 0
US: Laurie Doyle
T +1-339-832-0752
Email: invios@mc-services.eu


15.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2415926  15.10.2026 CET/CEST

BIOTECH SUMMIT AUSTRIA Highlights Growing Momentum Across Austria’s Biotech Sector

BIOTECH AUSTRIA

/ Key word(s): Miscellaneous

BIOTECH SUMMIT AUSTRIA Highlights Growing Momentum Across Austria’s Biotech Sector

15.10.2026 / 08:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


BIOTECH SUMMIT AUSTRIA Highlights Growing Momentum
Across Austria’s Biotech Sector

Innsbruck, Austria – October 15, 2026. The fourth BIOTECH SUMMIT AUSTRIA brought together leading voices from research, industry, startups, investment and policy in Innsbruck this week. Jointly organized by BIOTECH AUSTRIA, Human.technology Styria and Standortagentur Tirol, the summit serves as a national meeting point for Austria’s biotech sector with growing international participation and this year drew more than 250 participants from 12 countries.

Held under the motto “Start up, Scale up, Step up!”, the program reflected the journey from scientific discovery and company creation through financing and organizational growth to international expansion and long-term impact. Across the two-day agenda, keynotes, panel discussions, workshops and startup pitches explored the opportunities, challenges and next steps for Austria’s biotech community as it continues to grow and connect internationally.

Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, commented: “Austria has a strong scientific foundation, but one decisive question is how we translate that strength into companies that can grow and compete internationally. This year’s summit brought together researchers, entrepreneurs, investors and policymakers who all play a role in making that transition possible. The discussions demonstrated the growing ambition of the Austrian biotech sector as well as the importance of continued collaboration to unlock its full potential. My thanks go to our speakers, participants, sponsors and co-hosts for making Innsbruck such a productive meeting point for the sector.”

The keynote program featured former STADA AG CEO Claudio Albrecht, who explored how geopolitical shifts, technological innovation, changing healthcare systems and new business models could shape the pharmaceutical industry through 2035. Karl Nehammer, Vice President of the EIB and former Federal Chancellor of Austria, addressed the conditions needed for European biotech innovators to grow and compete globally. Olympic sailing champion Lukas Mähr drew on his experience to explore resilience and teamwork, while Stefan Haubner, Founding Partner at APEX Ventures, considered whether European venture capital needs a model of its own. Further sessions addressed topics such as venture financing, global IP strategy, AI in biotech investment and Austrian biotech strategy and policy. The program concluded with a fireside chat between BioNTech founder and investor Christoph Huber and Peter Llewellyn-Davies, reflecting on experiences and lessons from building successful biotech ventures.

Anton Mattle, Governor of Tyrol, commented: “Biotechnology is an important driver of innovation and future economic development. Events such as the BIOTECH SUMMIT AUSTRIA showcase Tyrol’s strengths in life sciences and create valuable connections between science, business and policy. They also contribute to strengthening Austria’s international visibility and support the exchange of ideas and partnerships that help innovative companies grow.”

Networking and partnering remained a central element of the summit. Dedicated 1:1 meetings and social events gave participants from across the biotech value chain opportunities to establish new relationships, deepen existing connections and explore future potential collaborations beyond the conference sessions.

Marcus Hofer, CEO of Standortagentur Tirol and local host of the summit, and Lejla Pock, CEO of Human.technology Styria, added: “Bringing the summit to different regions allows us to showcase their individual strengths while fostering exchange and collaboration across Austria’s biotech community and beyond. Innsbruck provided an excellent setting for discussions, new connections and future partnerships. We look forward to building on this momentum when the summit moves to Graz in 2027.”

The fourth BIOTECH SUMMIT AUSTRIA concluded with a closing reception and a handover to the next host location: The discussions in Innsbruck reflected a sector that is gaining momentum, strengthening international connections and working together to translate scientific excellence into lasting economic and societal impact. The fifth BIOTECH SUMMIT AUSTRIA will take place in Graz on 21-22 October 2027.

For further information and to revisit highlights of the fourth BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA website.

For post-event inquiries and additional information, please contact:

BIOTECH AUSTRIA
Christine Llewellyn-Davies
Head of Operations
+43 670 6030601
Email: info@biotechaustria.org

Human.technology Styria
Lejla Pock
CEO
Eva Bucht
PR & Marketing
+43 699 188 99 708
Email: office@human.technology.at

Standortagentur Tirol
Marcus Hofer
CEO Standortagentur Tirol
Albert Bloch
Communication & Press
+43 676 843 101-270
Email: albert.bloch@standort-tirol.at

Media Contact

MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
+49 89 210 228 0
Email: biotechaustria@mc-services.eu

About BIOTECH AUSTRIA

Since December 2020, BIOTECH AUSTRIA has been the voice of the Austrian biotech industry, enabling and connecting a non-governmental ecosystem so that businesses can start, grow and deliver world-changing innovation. Life Sciences are a key industry in Austria, and biotechnology is one of the fastest-developing sectors with high growth dynamics and international competitiveness. BIOTECH AUSTRIA is constantly expanding its network with new members and supporters in order to gather even more expertise under one roof. BIOTECH AUSTRIA represents over 100 biotech and life science companies, from start-ups to big pharma, academic institutions, research institutes, organisations and service providers to the sector. More information can be found at www.biotechaustria.org or on LinkedIn.

About Human.technology Styria

Human.technology Styria GmbH (HTS) is a cluster organization founded in 2004 with a focus on Life Sciences. It operates in three strategic priority areas: Medical Technology, Pharmaceuticals & Biotechnology, and Health & Sustainability. Additionally, HTS is actively involved in cross-cutting topics such as Start-Ups, Digitalization, and Qualification. The cluster sees itself as a bridge-builder between research, development, and industry, aiming to create synergies, enable innovations, forge new partnerships, and enhance the national and international visibility of the region. Companies within the cluster community benefit from exclusive service offerings related to Contact Management, Business Development, Internationalization, Networking, Events, Communication, and Knowledge Transfer. Within the environment of the Styrian Life Science Cluster, there are 150 companies with 40,000 employees generating a turnover of 5 billion euros. Approximately one-third of this can be attributed to the Pharma/Biotech sector. More information can be found at www.humantechnology.at.

About Standortagentur Tirol / Health Hub Tirol

Tirol is a strong life sciences location. Successful companies and outstanding universities ensure a high research output, over 11,000 jobs and an industry turnover of almost 3 billion euros per year. Almost 100 innovative companies, institutions and universities are networked in the Cluster Life Sciences Tirol, which is based at the Standortagentur Tirol. In addition, the state of Tirol invests in a location development program for life sciences via Lebensraum Tirol Holding, which is implemented by Standortagentur Tirol and its subsidiaries. This program aims to drive innovation in the fields of medical technology, digital health, pharmaceuticals and biotechnology. Tirol is to be positioned as a top European life sciences region by 2030. One pillar of the program is the Health Hub Tirol, which works closely with the Cluster Life Sciences Tirol and Startup.Tirol to provide (lab) space and a wide range of startup services. More information can be found at www.standort-tirol.at and www.healthhub.tirol.


15.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2415826  15.10.2026 CET/CEST

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Evotec SE

/ Key word(s): Miscellaneous

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

15.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
 

  • Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation
  • Brings more than 25 years of global experience in pharma, biotechnology and academia
 

Hamburg, Germany, October 15, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal ‘omics, data science, novel therapeutic modalities and precision medicine, complemented by experience in commercializing innovative technologies, shaping drug discovery partnerships and leading therapeutic research portfolios. At Evotec, Dr. Holbrook will draw on recent scientific advances to help customers and partners discover and develop new medicines faster and with a higher probability of success.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today. She combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results. I look forward to working with her as we continue to strengthen Evotec’s position as a leading partner for any organization that strives to bring new, groundbreaking medicines to market.”

Dr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Prior to that she held positions at UK biotech companies Biomodal, where she served as Chief Scientific Officer, and BenevolentAI, where she was Vice President, Translational Medicine. She was also Professor of Bioinformatics at the University of Southampton and Senior Principal Investigator at the Singapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at National University of Singapore. She started her career at GSK, where she held positions of increasing responsibility across therapy areas and bioinformatics. She holds a Ph.D. in Molecular Cell Biology from University College London and a B.Sc. in Genetics from the University of Newcastle.

Dr. Joanna Holbrook, Evotec’s incoming Chief Scientific Officer, added:

“Evotec has exceptional breadth of scientific expertise and capabilities spanning drug discovery, drug development and manufacturing. I am excited by the opportunity to work across the business to strengthen our scientific differentiation, build integrated solutions to the most important challenges in drug discovery, and develop new capabilities that are unique to Evotec.”

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 


15.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2414804

 
End of News EQS News Service

2414804  15.10.2026 CET/CEST